The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study
- PMID: 34884357
- PMCID: PMC8658414
- DOI: 10.3390/jcm10235656
The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study
Abstract
A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the years 2015 and 2016. A total of 438 primary care physicians enrolled 13,724 adult patients that sought medical care in primary health care practices. The prevalence of hypertension, diabetes mellitus, dyslipidaemia, and CVD were similar in urban and rural areas (49.5 vs. 49.4%; 13.7 vs. 13.1%; 84.2 vs. 85.2%; 14.4 vs. 14.2%, respectively). The prevalence of obesity (32.3 vs. 37.5%, p < 0.01) and excessive waist circumference (77.5 vs. 80.7%, p < 0.01), as well as abdominal obesity (43.2 vs. 46.4%, p < 0.01), were higher in rural areas in both genders. Mean levels of LDL-C (128 vs. 130 mg/dL, p = 0.04) and non-HDL-C (147 vs. 148 mg/dL, p = 0.03) were slightly higher in rural populations. Altogether, 14.3% of patients with CVD from urban areas and 11.3% from rural areas reached LDL <70 mg/dL (p = 0.04). There were no important differences in the prevalence of hypertension, diabetes, dyslipidaemia, and CVD, or in mean levels of blood pressure, cholesterol fractions, glucose, and HbA1c between Polish urban and rural primary care patient populations. A high proportion of patients in cities and an even-higher proportion in rural areas did not reach the recommended targets for blood pressure, LDL-C, and HbA1c, indicating the need for novel CVD-prevention programs.
Keywords: Poland; cardiovascular diseases; primary health care; risk factors; rural; urban.
Conflict of interest statement
J.J.J. and M.B. have received an unrestricted educational grant from Valeant, and served as a consultant or speaker for Valeant. T.T. has served as a consultant or speaker for Boehringer Ingelheim, Biofarm, AstraZeneca, Novo Nordisk Pharma. P.E.P. owns four shares in AstraZeneca PLC and has received honoraria and/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Mylan, Napp, and Sanofi. D.P.M. has given talks, acted as a consultant, or attended conferences sponsored by Amgen, Novo Nordisk, and Libytec. All other authors have no conflict of interest concerning the results of this analysis. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures



References
-
- GBD 2017 Causes of Death Collaborators Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–1788. doi: 10.1016/S0140-6736(18)32203-7. - DOI - PMC - PubMed
-
- Wilkins E., Wilson L., Wickramasinghe K., Bhatnagar P., Leal J., Luengo-Fernandez R., Burns R., Rayner M., Townsend N. European Cardiovascular Disease Statistics 2017. European Heart Network; Brussels, Belgium: 2017.
-
- Jóźwiak J.J., Studziński K., Tomasik T., Windak A., Mastej M., Catapano A.L., Ray K.K., Mikhailidis D.P., Toth P.P., Howard G., et al. The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: Results from the LIPIDOGRAM2015 study. Atheroscler. Suppl. 2020;42:e15–e24. doi: 10.1016/j.atherosclerosissup.2021.01.004. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources